REAL-COLOR VERSUS PSEUDO-COLOR IMAGING OF FIBROTIC SCARS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
11
2
2020
medline:
4
9
2021
entrez:
11
2
2020
Statut:
ppublish
Résumé
To compare the morphological characteristics of subretinal fibrosis in late age-related macular degeneration using multicolor (MC) imaging, color fundus photography (CFP), and ultra-widefield CFP (UWFCFP). Thirty-two eyes of 31 patients diagnosed with subretinal fibrosis complicating exudative age-related macular degeneration were included. Included eyes were imaged by MC, CFP, and UWFCFP. The overall ability to visualize fibrosis, its margins, and dissimilarity with surrounding atrophy was graded using a score (0: not visible, 1: barely visible, 2: mostly visible, and 3: fully visible) by two readers. Area of fibrosis was calculated. Scaling, lesion colocalization on all three imaging techniques, and area measurements were performed using ImageJ. Ninety-six images of 32 eyes were graded. The average area of fibrosis was 14.59 ± 8.94 mm for MC, 13.84 ± 8.56 mm for CFP, and 13.76 ± 8.79 mm for UWFCFP. Fibrosis was fully visible in 87.5% of cases using MC and 50% using CFP and UWFCFP. Fibrosis' margins were sharply defined in 40.6% of eyes with MC, 15.6% and 9.4% with CFP and UWFCFP, respectively. Multicolor imaging provided superior distinction between fibrosis and atrophy (100% for MC vs. 13.4% for CFP and 33.3% for UWFCFP). The inter- and intra-reader agreement was high for all measurements (P < 0.0001). Multicolor technology allows for improved visualization and analysis of subretinal fibrosis when compared with CFP and UWFCFP, especially when surrounding atrophy is present.
Identifiants
pubmed: 32039941
doi: 10.1097/IAE.0000000000002771
pii: 00006982-202012000-00004
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2277-2284Références
Evans JR, Fletcher AE, Wormald RPL, et al. Prevalence of visual impairment in people aged 75 years and older in Britain: results from the MRC trial of assessment and management of older people in the community. Br J Ophthalmol 2002;86:795–800.
Evans JR, Fletcher AE, Wormald RPL. 28,000 Cases of age related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking. Br J Ophthalmol 2005;89:550–553.
Gordois A, Cutler H, Pezzullo L, et al. An estimation of the worldwide economic and health burden of visual impairment. Glob Public Health 2012;7:465–481.
Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet 2012;379:1728–1738.
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444.
Bloch SB, Lund-Andersen H, Sander B, Larsen M. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab. Am J Ophthalmol 2013;156:116–124.e1.
Channa R, Sophie R, Bagheri S, et al. Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. Am J Ophthalmol 2015;159:9–19.e1–2.
Toth LA, Stevenson M, Chakravarthy U. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: outcomes in Eyes with Poor Initial Vision. Retina 2015;35:1957–1963.
Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011;118:523–530.
Cohen SY, Oubraham H, Uzzan J, et al. Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings. Retina 2012;32:1480–1485.
Kernt M, Schaller UC, Stumpf C, et al. Choroidal pigmented lesions imaged by ultra-wide-field scanning laser ophthalmoscopy with two laser wavelengths (Optomap). Clin Ophthalmol 2010;4:829–836.
Ben Moussa N, Georges A, Capuano V, et al. MultiColor imaging in the evaluation of geographic atrophy due to age-related macular degeneration. Br J Ophthalmol 2015;99:842–847.
Pang CE, Freund KB. Ghost maculopathy: an artifact on near-infrared reflectance and multicolor imaging masquerading as chorioretinal pathology. Am J Ophthalmol 2014;158:171–178.e2.
Graham KW, Chakravarthy U, Hogg RE, et al. Identifying features of early and late age-related macular degeneration: a comparison of multicolor versus traditional color fundus photography. Retina 2018;38:1751–1758.
Kilic Muftuoglu I, Bartsch DU, Barteselli G, et al. Visualization of macular pucker by multicolor scanning laser imaging. Retina 2018;38:352–358.
Anon. Retinal physician—focus on. Retinal physician. Available at: https://www.retinalphysician.com/issues/2012/july-aug/focus-on. Accessed October 15, 2018.
Bruyère E, Caillaux V, Cohen SY, et al. Spectral-domain optical coherence tomography of subretinal hyperreflective exudation in myopic choroidal neovascularization. Am J Ophthalmol 2015;160:749–758.e1.
Ores R, Puche N, Querques G, et al. Gray hyper-reflective subretinal exudative lesions in exudative age-related macular degeneration. Am J Ophthalmol 2014;158:354–361.
Tan ACS, Fleckenstein M, Schmitz-Valckenberg S, Holz FG. Clinical application of multicolor imaging technology. Ophthalmologica 2016;236:8–18.
Querques G, Srour M, Massamba N, et al. Reticular pseudodrusen. Ophthalmology 2013;120:872–872.e4.
Chakravarthy U, Jaffe GJ. Dual Antagonism of Platelet Derived Growth (Fovista 1.5 mg) and Vascular Endothelial Growth Factor (Lucentis 0.5 mg) Results in Reduced Subretinal Fibrosis and Neovascular Growth. American Academy of Ophthalmology Annual Meeting 2014, Oct. 18-21, Chicago, IL.
Shah VP, Shah SA, Mrejen S, Freund KB. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration. Retina 2014;34:1281–1288.
Daniel E, Toth CA, Grunwald JE, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014;121:656–666.
Daniel E, Ying G, Kim BJ, et al. Five-year follow-up of nonfibrotic scars in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2019;126:743–751.
Kuiper EJ. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol 2006;124:1457.
Miere A, Semoun O, Cohen SY, et al. Optical coherence tomography angiography features of subretinal fibrosis in age-related macular degeneration. Retina 2015;35:2275–2284.